| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.6 | 0.6 |
| Net income | -3.8 | -5.4 |
| EPS (diluted, $ a share) | $-0.21 | $-0.99 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +157.3% |
|---|---|
| Operating margin | -206.6% |
10-Q filed with the SEC, NYSE: VNRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Volitionrx Ltd: key numbers
- Share price
- $0.1998Close, Nov 16
- Market cap
- $7.21M
- Shares outstanding
- 36.08MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Volitionrx Ltd
All →Volitionrx Financial Results
VolitionRx reported financial results for the third quarter of 2026, highlighting progress in its Nu.Q platform across sepsis, lung cancer, and veterinary diagnostics. The company noted the launch of the French government-funded DETECSEPS program and active licensing discussions for its Capture-Seq technology in the liquid biopsy market.
- Term
- Q3 2026
“It has been a very full quarter as we have continued to execute our plan to commercialize our game-changing Nu.Q® platform. We have made strong progress across our key product pillars this year, evidencing clinical utility across a broad spectrum of indications whilst driving commercialization and licensing efforts worldwide. At the same time, we have taken decisive action to strengthen our financial profile by cutting costs and significantly reducing convertible note debt.”
Cameron Reynolds, President and Group Chief Executive Officer
Volitionrx Executive Compensation
VolitionRx CEO Cameron Reynolds agreed to a further temporary reduction in his annual base salary from $355,456 to $236,970.50 as part of the company's cost-reduction measures. This follows a previous 25% reduction effective February 2026, bringing his total salary down from a contractual base of $473,941. The reduction will remain in effect until the Compensation Committee determines the company's financial stability is secured, potentially following a significant licensing or commercial agreement.
- Term
- temporary
Volitionrx $500K Debt Financing with Lind Global Asset Management XII LLC
VolitionRx entered into a waiver and consent agreement with Lind Global Asset Management to make a $500,000 partial cash prepayment on a senior secured convertible promissory note, reducing the outstanding balance to approximately $0.7 million. The agreement also defers monthly repayments for November and December 2026 and pauses Lind's conversion rights until January 1, 2027, unless the stock price reaches $0.275.
- Value
- $500K
- Counterparty
- Lind Global Asset Management XII LLC
Volitionrx $525K Debt Financing with Lind Global Asset Management XII LLC
VolitionRx Limited issued an aggregate of 2,157,340 shares of common stock to Lind Global Asset Management XII LLC to satisfy $525,000 in conversion obligations under a senior secured convertible promissory note. The shares were issued in two tranches on September 18 and September 23, 2026, as part of the settlement of an existing debt instrument originally issued in May 2025.
- Value
- $525K
- Counterparty
- Lind Global Asset Management XII LLC
Volitionrx Debt Financing Update with Lind Global Asset Management XII LLC
VolitionRx Limited issued a total of 1,413,450 shares of common stock to Lind Global Asset Management XII LLC to satisfy $465,000 in conversion obligations under existing senior secured convertible promissory notes. The shares were issued in two tranches on September 2 and September 10, 2026, as part of the settlement of debt obligations originally established in May 2025.
- Counterparty
- Lind Global Asset Management XII LLC
Volitionrx Debt Financing Update with Lind Global Asset Management XII LLC
VolitionRx Limited has prepaid in cash the remaining outstanding principal amount of approximately $422,000 on its senior secured convertible promissory note issued in May 2025. Following this payment, no further obligations remain under the 2025 Note, although a separate 2026 Note with Lind Global Asset Management remains in effect. This action reduces the company's outstanding debt and settles the specific 2025 financing obligation.
- Counterparty
- Lind Global Asset Management XII LLC